Wednesday, 16 Oct 2019

You are here

Population-Based TB Risk and Prevention with RA and Biologics

In a retrospective cohort comparison study, 42,180 rheumatoid arthritis (RA) patients were compared 1:4 with 168,000 normal controls to examine the incidence of new tuberculosis in Taiwan. The RA population included those receiving csDMARDs (36,162), etanercept (3,577), adalimumab (1,678) and rituximab (763). 

In Taiwan, BCG vaccination is implemented universally.  Hence, a TB diagnosis was based on the use of an interferon gamma releasing assay (IGRA), and if results were indeterminate, TST would be performed using the Mantoux method. Patients were enrolled after TB screening. New TB cases were confirmed by coding, record review or death.

TB risk was 2.7-fold higher in RA patients compared with non-RA group, with an adjusted hazard ratio (aHR) of 2.58. Risk factors for TB included advanced age, male, corticosteroids≧5mg/day, and comorbidities (diabetes mellitus, chronic obstructive pulmonary disease chronic kidney disease). The time to develop new TB after drug exposure was shortest for  adalimumab (1.8±1.2 years), followed by etanercept (3.6±2.4 years), and longest for csDMARDs (6.8±3.7 years).

Using RA  patients on csDMARDs as reference, aHR for TB was the highest with adalimumab (1.52), etanercept (1.16), and lowest with rituximab (0.08).  

A total of 913 TB cases were identified in 231,759 csDMARDs-exposed patients (IR = 394 per 100,000py) with a higher risk of TB (aHR = 2.47, 95% CI 2.29–2.67, p<0.001) compared with non-RA group. RA patients were twice as likely as non-RA patients to have extrapulmonary TB (11% vs. 6.5 %). RA patients with new TB had a 2.5 fold higher mortality rate that was further increased by age, DM, and steroid use.

INH prophylaxis was used in those with latent TB infection (LTBI) and was shown to be 55-100% effective at lowering the risk of subsequent TB in those who continued their biologic.

The risks of TB and the mortality associated with TB may be efficiently reduced through increased awareness, comprehensive screening and effective use of INH prophylaxis.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Hydroxychloroquine Blood Levels May Predict Future Retinopathy

A study of 527 patients receiving daily hydroxychloroquine (HCQ) concluded that hydroxychloroquine blood levels may predict future HCQ retinopathy.

This study assessed whether lower HCQ dosing, as recommended by the 2016 American Academy of Ophthalmology (AAO) guidelines (less than 5 mg/kg), would favorably affect retinopathy outcomes.

Arthritis Foundation Releases First CBD Guidance for Adults With Arthritis

As the leading organization for people with arthritis, the Arthritis Foundation has just released the first CBD guidance for adults with arthritis. CBD, or cannabidiol, a plant-based compound, has become popular among people with arthritis seeking to ease chronic joint pain.

Persistent Inflammatory Arthritis After Immune Checkpoint Inhibitors

Braaten and colleagues from Johns Hopkins School of Medicine have reported their experience with chronic inflammatory arthritis induced by immune checkpoint inhibitor therapies, showing that in some, inflammatory arthritis persists after the immunotherapy has been discontinued.

Checkpoint Inhibitors: Who Gets Myocarditis?

The usual risk factors for myocarditis may not apply to who gets it while on immune checkpoint inhibiting cancer drugs, an FDA adverse event database suggested.

NSAIDs Mediate Cardiovascular Risk in OA

NSAIDs have been linked to an increased risk of cardiovascular disease, but does this also hold for osteoarthritis (OA) patients.